Cost of Healthcare-Associated Infections (HAIs) in APEC Economies

A Review of the Literature

APEC Health Working Group
Life Sciences Innovation Forum

November 2013
November 2013
This publication was produced by Nathan Associates Inc. for review by the United States Agency for International Development.

Self-funded project endorsed by HWG and LSIF
APEC#213-HT-05.1
Cost of Healthcare-Associated Infections (HAIs) in APEC Economies
A Review of the Literature

November 2013

This publication was produced by Nathan Associates Inc. for review by the United States Agency for International Development.
Cost of Healthcare-Associated Infections (HAIs) in APEC Economies

A Review of the Literature

DISCLAIMER

This document is made possible by the support of the American people through the United States Agency for International Development (USAID). Its contents are the sole responsibility of the author or authors and do not necessarily reflect the views of USAID or the United States government.
Figure 4-9. Model Output for 'Bed Day' Costs' of BSI  
Figure 4-10. Model Output for 'Total Costs' of BSI  
Figure 4-11. Completeness of Data Needed for Studies to Describe HAI Costs in All APEC Economies

Tables
Table 3-1. Extra Lengths of Stay Found by Each Study  
Table 3-2. Incidence Rates and Point Prevalence Found by Each Study  
Table 4-1. Prediction Measures and Level of Uncertainty for Each  
Table 4-2. Economic Indicators for Hospitals and Level of Uncertainty for Each
Executive Summary

The APEC Health Working Group and Life Sciences Innovation Forum (LSIF) have been leading efforts in the region to advance understanding of the economic and public health impact of healthcare-associated infections (HAIs). Enhancing awareness of the prevalence and costs of HAIs is a critical element for the development and analysis of policies that aim to reduce waste in healthcare systems and improve the quality and efficiency of care. This is particularly important at a time when many APEC economies are actively expanding and investing in their healthcare systems and are seeking to ensure the best utilization of scarce resources. However, efforts to do so can be impeded by a lack of quality data on the prevalence and costs of HAIs.

In many developed economies within APEC a robust body of published literature demonstrates the costs of HAIs and provides a basis for policies and protocols to reduce their incidence and improve the quality and efficiency of care. However, in many developing economies there is a deficit of data. A deficit of data in itself is not an indication that HAIs are not imposing significant adverse costs to an economy’s healthcare systems. Rather, a deficit of data could present a costly missed opportunity for economies to integrate sound policies to promote efficiency at a critical time when many are rapidly expanding their health systems to meet the needs of growing populations and economic activity.

This report aims to add to the dialogue on HAIs by assessing the available studies on the costs and length of hospital stay attributable to HAIs in APEC economies. The analysis is conducted in three parts: (1) a search for existing data; (2) an evaluation of the data quality and completeness; and (3) a discussion on future research to inform policy.

The search for existing data resulted in a variable quantity and quality of data across the studied APEC economies. This is not surprising given the current state of infrastructure and investment in infection prevention and control within healthcare settings. The analysis then turned to an attempt to develop a model based on existing data. In order to accomplish this, four parameters are identified: (1) information on the incidence rates of HAIs is needed; (2) information is required to describe the extra time a patient must receive care in a healthcare setting due to an incidence of an HAI (referred to as the length of stay per case); (3) the treatment costs need to be understood; and (4) the economic value of bed days lost to HAIs needs to be understood.

The results of the model indicate costs attributable to HAIs, but with a high degree of variability and uncertainty. This reflects the quality of available data and is not surprising. Because of the uncertainties, it is difficult to draw conclusions and policy recommendations directly from the model. However, the results, coupled with the strong body of evidence of the costs of HAIs in developed economies, indicate that further study of the economic impact
of HAIs is warranted in the developing economies within APEC to ensure that inefficiencies in healthcare delivery are appropriately identified, measured, and reduced.

This analysis leads to support for recommendations endorsed by APEC for member economies to establish collection of surveillance data on HAIs in order to better quantify the problem and identify cost-effective solutions to improve the efficiency and quality of healthcare delivery.
1. Background

The APEC Health Working Group and Life Sciences Innovation Forum (LSIF) have been exploring the public health and economic impact of healthcare-associated infections (HAIs) in member economies. In July 2012 in Manila, Republic of the Philippines, APEC hosted the first of its kind "APEC High-Level Workshop on Reducing the Economic Burden of Healthcare-Associated Infections," which produced a series of recommendations at both the economy and institutional levels. Subsequently, in July 2013 in Medan, Indonesia, APEC hosted an "APEC HWG-LSIF Policy Dialogue on Building Capacity to Address HAIs," during which a toolkit for policymakers to consider as they evaluate and develop policies to address HAIs was submitted for APEC consideration, along with proposed "APEC Medan Principles for Public-Private Partnerships in Infection Prevention & Control." In order to supplement and support the ongoing work of APEC in HAIs, the APEC Technical Assistance and Training Facility requested a review of literature on the economic impact of HAIs in developing APEC economies.

Having a robust awareness of the prevalence of HAIs provides a foundation for the development and analysis of policies that aim to reduce waste in healthcare systems and improve the quality and efficiency of care. While policies at the economy level and clinical interventions at the institutional level need to be evaluated for their effectiveness, efforts to do so can be impeded by a lack of quality surveillance data on HAIs. In many developed economies within APEC, data on the prevalence of healthcare-associated infections (HAIs) and the costs that they incur on healthcare systems are well-documented. However, data on the economic impact of HAIs in many developing economies within APEC are not as well documented. A deficit of data in itself is no indication that HAIs are not imposing significant adverse costs to an economy's healthcare systems. Rather, a deficit of data could present a costly missed opportunity for economies to integrate sound policies to promote efficiency at a critical time when many are rapidly expanding their health systems to meet the needs of growing populations and economic activity.

Measuring and valuing the costs of healthcare associated infection (HAI) is a difficult yet important consideration for any decision to strengthen public policies and protocols and increase investment in infection control programs. They represent the potential savings that will offset the positive costs of an essential infection control program, such as increasing hand hygiene compliance. The health benefits of decreased morbidity and mortality from reduced infections must also be quantified [1].

The costs of HAIs are likely to be diffused throughout healthcare services, and there are private and difficult-to-value costs like pain and suffering for patients and inconvenience and stress for their families. In the US around 99,000 deaths were attributed to HAIs in 2002, and the annual HAI-associated economic costs were estimated at US$6.5 billion [2]. In European
developed economies, HAIs cause 16 million extra days of hospital stay, direct medical costs of €7 billion a year, and an additional 110,000 deaths [3,4].

The largest component of total costs will arise from prolongation of stay in acute care hospitals due to HAIs [5]. The opportunity cost of numbers of bed days lost to HAIs is a key statistic to be included in any economic argument for making investments in prevention programs. At least three tasks need to be achieved to measure the cost of lost bed days: The frequencies of infections need to be counted reliably; the extra days stay per average case need to be quantified; and the economic value of the bed days needs to be found. There are challenges at every stage with definitions, accurate diagnoses, and the routine surveillance of HAIs [6,7]. When attributing extra stay to an average case of HAI, the large biases arising from time dependency need to be controlled [8-10]. When valuing bed days, economic rather than accounting costs need to be used [11]. The real value of bed days depends on the need to access hospital services among the general population and the willingness of decision makers to pay for these.

HAIs introduce inefficiencies into healthcare systems and health risks for patients and are a challenge for those who manage healthcare services in all economies. In developing economies, risks may be higher. However, these economies are also constrained in available funding for infection control, and therefore there is a strong need to show how costs can be reduced and health benefits increased by investing in infection control. Knowledge of the economic impact of HAIs in middle-income settings is low because data on HAIs are incomplete and almost nonexistent in developing economies.

At present there is no systematic review undertaken to assess the economic impact of HAIs in developing economies. While HAI surveillance systems are in place at the national or sub-national level in many developed economies, less than 16 percent of developing economies reported a functioning national surveillance system, according to a survey conducted by the WHO [4,12].

This report aims to systematically assess available studies on the costs and length of hospital stay (LOS) attributable to HAIs in APEC economies. Because we currently have good knowledge of the costs of HAIs in North America [2] and Australia [13] these economies are excluded, and the work concentrates on the remaining economies. This report has four sections:

- Searching for data
- Data quality and completeness
- Future research to inform policy
- Summary
2. Searching for Data

We undertook a systematic literature search to identify studies on the costs and LOS attributable to healthcare associated infection in APEC economies. We excluded North America and Australia, for which separate searches have been conducted. We searched CINAHL, PubMed, and EconLit using MeSH and non-MeSH terms including "cross infection," "healthcare acquired infection," "hospital acquired infection" and "nosocomial infection," combined with "healthcare costs," "hospital costs," "treatment costs," "economics," and "length of hospital stay." In addition, we searched Google and Google Scholar for relevant studies. Reference lists of retrieved cost studies and systematic reviews were examined to locate relevant studies for inclusion. We limited the above searches to studies published in English between January 1, 2000, and April 30, 2013. The detailed search strategies are in Appendix A.

SELECTION CRITERIA

Studies were included if their measures of outcomes included costs and LOS attributable to HAIs in APEC economies (excluding Australia, Canada, and the United States). Studies were excluded if they reported only incidence and prevalence of HAIs, or costs or LOS unrelated to HAIs. Studies on HAI-associated costs and LOS in non-APEC economies were excluded. The detailed selection process is in Figure 2-1.

DATA EXTRACTION

Two independent reviewers conducted the selection of studies for inclusion and data extraction. Discrepancies were resolved by consensus. The extracted data included: authors, year of publication, economy and study setting, study design, study period, study population, site and type of HAI, incidence, prevalence, study method, HAI-associated LOS and costs, and currency of denomination. The data extracted from the selected studies are shown in Appendix B.

SEARCH RESULTS

The search strategy yielded 632 studies after removing duplicates; of those 632 studies, 18 studies met the selection criteria for inclusion (Figure 2-1).
Three studies were conducted in New Zealand [14-16]; seven in Chinese Taipei [17-23]; two in Thailand [24,25]; and one each in Japan [26], Singapore [27], China [28], Korea [29], Mexico [30], and Malaysia [31].
As for design, 10 were matching studies [14, 16, 17, 19-23, 27, 29, 30], one was a modeling study based on published estimates [15], three were attribution studies from expert review [25, 31, 32], and three were based on statistical regression models [18, 22, 26].

The types of infection included were bloodstream [14, 15, 17, 21, 23, 29-31], urinary tract [15, 21, 23, 31], surgical site [15, 16, 21, 23, 31], chest [15, 21, 23, 31], other and multiple sites of HAI [15], methicillin-resistant Staphylococcus aureus [27], Acinetobacter [19, 20] and an influenza outbreak [32].
The patient groups studied included the following groups: all hospital patients [14, 19, 21, 22, 25, 27, 29, 31, 32]; general medical and surgical patients [15]; coronary artery bypass grafting (CABG) patients [16]; pediatrics patients [28]; hemodialysis patients [17]; intensive care unit (ICU) patients [18, 20, 23, 30]; and stroke patients [26].

**Figure 2-5**
*Patient Groups Studied*
3. Data Quality and Completeness

The extra lengths of stay estimated by each study for the different types of HAI are shown in Table 3-1. There is large variability among these results with bloodstream infections (BSI) found to prolong stays between 5 and 18.9 days, surgical site infections (SSI) between 7 and 32.2 days, and urinary tract infections (UTI) between 2 and 17.5 days. This high degree of uncertainty means we know little about the factors that influenced the actual increased stay caused by these infections. The incidence rates and point prevalences reported for each study for the different types of HAI are shown in Table 3-2.

**Table 3-1**
*Extra Lengths of Stay Found by Each Study*

<table>
<thead>
<tr>
<th>Reference</th>
<th>Economy</th>
<th>Patient Group Studied</th>
<th>Estimated Extra Stay (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>[14]</td>
<td>NZ</td>
<td>All hospital patients</td>
<td>BSI = 9.7 or 7.9</td>
</tr>
<tr>
<td>[15]</td>
<td>NZ</td>
<td>General medical &amp; surgical</td>
<td>BSI = 5; UTI = 2 (medical) &amp; 4 (surgical); SSI = 8 (medical) &amp; 10 (surgical); Chest = 6; other = 5</td>
</tr>
<tr>
<td>[16]</td>
<td>NZ</td>
<td>CABG patients</td>
<td>SSI = 32.2</td>
</tr>
<tr>
<td>[29]</td>
<td>Korea</td>
<td>All hospital patients</td>
<td>BSI = 18.9</td>
</tr>
<tr>
<td>[28]</td>
<td>China</td>
<td>Pediatrics</td>
<td>All HAIs = 5</td>
</tr>
<tr>
<td>[27]</td>
<td>Singapore</td>
<td>All hospital patients</td>
<td>All MRSA = 25</td>
</tr>
<tr>
<td>[17]</td>
<td>Chinese Taipei</td>
<td>Hemodialysis</td>
<td>BSI = 14</td>
</tr>
<tr>
<td>[18]</td>
<td>Chinese Taipei</td>
<td>ICU patients</td>
<td>All HAIs = 27</td>
</tr>
<tr>
<td>[19]</td>
<td>Chinese Taipei</td>
<td>All hospital patients</td>
<td>Acinetobacter = 13.4</td>
</tr>
<tr>
<td>[20]</td>
<td>Chinese Taipei</td>
<td>ICU patients</td>
<td>Acinetobacter = 8.7 (ICU) and 19.1 (ward)</td>
</tr>
<tr>
<td>[22]</td>
<td>Chinese Taipei</td>
<td>All hospital patients</td>
<td>All HAIs = 19.2; BSI = 15.5; UTI = 17.5; SSI = 14.4; Chest = 18.4</td>
</tr>
<tr>
<td>[21]</td>
<td>Chinese Taipei</td>
<td>All hospital patients</td>
<td>All HAIs = 15</td>
</tr>
<tr>
<td>[23]</td>
<td>Chinese Taipei</td>
<td>ICU patients</td>
<td>BSI (N/A)</td>
</tr>
<tr>
<td>[25]</td>
<td>Thailand</td>
<td>All hospital patients</td>
<td>All HAIs = total stay 22.9 (not extra stay)</td>
</tr>
<tr>
<td>[32]</td>
<td>Thailand</td>
<td>All hospital patients</td>
<td>Influenza outbreak (only $ estimated)</td>
</tr>
<tr>
<td>[26]</td>
<td>Japan</td>
<td>Stroke patients</td>
<td>All HAIs = 16-3 (range 5.1-25.1)</td>
</tr>
<tr>
<td>[30]</td>
<td>Mexico</td>
<td>ICU patients</td>
<td>BSI = 6.05</td>
</tr>
<tr>
<td>[31]</td>
<td>Malaysia</td>
<td>All hospital patients</td>
<td>Only treatment $ reported</td>
</tr>
</tbody>
</table>
Table 3-2  
Incidence Rates and Point Prevalence Found by Each Study

<table>
<thead>
<tr>
<th>Reference</th>
<th>Economy</th>
<th>Patient Group Studied</th>
<th>Estimated Incidence Rates and Point Prevalence (%)</th>
</tr>
</thead>
</table>
| [15]      | NZ      | General medical and surgical | BSI = 1.77/0.48  
UTI = 1.4/2.54  
SSI = 0.51/2.31  
Chest = 1.04/1  
Other = 1/0.88 |
6 (2008)  |
| [18]      | Chinese Taipei | ICU patients        | 10.2 |
| [19]      | Chinese Taipei | All hospital patients  | 55.6 episodes per 100,000 discharges (annual) |
| [20]      | Chinese Taipei | ICU patients        | 0.56 per 1,000 patient-days |
| [23]      | Chinese Taipei | ICU patients        | All HAI = 14.5  
Chest = 3.7  
BSI = 5.1  
UTI = 5.6SSI = 1.4 |
| [26]      | Japan   | Stroke patients       | All HAI = 16.4 (inter-hospital range of 4.7-28.3) |
| [30]      | Mexico  | ICU patients          | BSI = 7.1 |
| [31]      | Malaysia | All hospital patients (point prevalence)  | HAI = 13.9  
UTI = 12.2  
Chest = 21.4  
BSI = 12.2SSI = 11.2 |

The quality of the data is difficult to judge. Making unadjusted comparisons of the stays of those with and without HAIs is not useful due to other differences, unrelated to HAIs, between the two groups. For example, those with HAIs might have more comorbidities and more complex diagnoses, and so might generate quite different length-of-stay outcomes regardless of their HAI status. The challenge is to estimate the independent effect of HAIs on length of stay by making allowances for sources of biases. Graves and Weinhold [33] review the method of "direct attribution" used by the authors of these papers found by this review [25, 31, 32], and "comparative attribution" used by the authors of these papers found by this review [14, 16, 17, 19-23, 27, 29, 30]. Direct attribution requires experts to assess the prolongation of stay due to HAIs. This method has been suggested to be "subjective" and not reproducible [34]. Comparative attribution studies tend to be preferred as they are perceived as objective measures. Authors of these studies use data from a cohort of patients. Then, either (1) a subset of infected patients is manually matched with uninfected controls on variables thought likely to affect length of stay, such as age, sex, comorbidities; or (2) multivariable statistical regression models are built to describe the relationship between HAI and cost outcomes, with controls for other factors thought likely to affect cost outcomes [35]. A disadvantage of manual matching is that infected patients are being matched on a limited number of variables. Matching with greater than five or six variables requires a much larger size of controls, making the research costly and difficult and possibly biased because of "omitted variables." The likely consequence is that too much of the observed variation in cost is attributed to an HAI and the cost of the HAI is overstated [36]. If cases of infection are excluded from the analysis to allow matching on more variables, then a selection bias could arise, because not all cases have the same opportunity to be included in the comparison of lengths of stay.
The use of statistical regression avoids selection bias and offers the opportunity to reduce bias arising from omitted variables. A statistical regression model will show the association between length of stay and the independent variables of HAIs, and other observable factors that might explain variation. Another important source of bias arises from the relationship between an HAI and length of stay. We know that HAIs increase length of stay and evidence exists that a prolonged length of stay also increases the risks of HAIs. This reverse causality induces correlation between the error terms and the independent variables, leading to biased estimates and tests of hypotheses [37]. This problem is called “endogenous variables bias” and has been discussed in the context of HAIs [38, 39]. Graves and Weinhold [33, 40] describe the problem in detail and report preliminary attempts at a solution, using an instrumental variables method. Controlling bias from endogenous variables and interpreting the results of an unbiased model is a methodological challenge for future research. Great progress has been made in recent years with the application of multistate models that correctly account for the timing of events [8-11, 41-58] and produce estimates of extra stay that are free from time-related biases, this is a good example [44]. All the estimates of extra stay reported in Table 3-1 arose from studies that failed to account for the timing of the infection.

The incidence rates and point prevalences reported do not emerge from common definitions, audit methods or similar data collection processes [59]. It is highly likely that outcomes are being measured differently, making comparison or extrapolation unreliable.

In addition to the weaknesses of methods in the data discussed, they are also incomplete. An economic modeling study that aims to predict the costs of HAIs requires, for each site or type of infection, data to inform four separate parameters that are discussed below.

First, information on the incidence rates of HAI is needed, and this review identified patchy and poor quality data for this parameter. Second, information is required to describe the extra stay per case, and this review identified estimates that mostly used methods fraught with sources of bias. Third, the treatment costs need to be understood and we found limited information for this. Presumably, clinicians working in each of the economies could make fairly good estimates of the typical treatment protocol for HAIs. Finally, the economic value of bed days lost to HAIs needs to be understood. No information was found for this issue in the literature retrieved. Economists would take a different approach to valuing bed days from the approach taken by cost accountants. Economists would estimate the value of bed days in their next-best alternative use; they wish to find the opportunity cost of losing bed days to treat an HAI. Cost accountants would estimate the cash expenditures in the hospital per bed day by dividing total expenditure by total bed days. The goal of the hospital accountant is to keep the organization financially viable [60]. Opportunity cost is the appropriate value for decision making and represents the amount that someone is willing to pay to access the marginal bed day. As long as the effective demand exceeds supply for hospital-based services, marginal bed days will be economically valuable.
4. Future Research Needs

In order to predict the costs of HAIS in the APEC economies, an economic model needs to be built. Five parameters are essential, which are shown in the black boxes marked A to E below. This allows predictions to be made for the outcomes in the remaining boxes with rounded corners.

**Figure 4-1**

A Suggested Economic Model

- **At risk pop (A)** * **Incidence Rates (B)** = **Number of cases**
- **Number of cases** * **Extra Stay per Case (C)** = **Bed days lost**
- **Number of cases** * **Treatment Costs (D)** = **Total treatment costs $**
- **Bed days lost** * **Value per bed day (E)** = **Cost of bed days $**

The at-risk population (A) represents the number of hospital admissions who are at risk of acquiring an infection. These might be broad categories, such as “all surgical patients” or “all medical patients,” or could be subgroups, such as “ICU admissions” or “oncology patients.” Regardless, this is a simple parameter to measure and should be accessed from routine hospital-level statistics in many economies. The period in which the risk arises must be specified, such as 12 months. In order to build a hypothetical case illustrating the method, we will assign 1,400 ICU patients admitted to a 20-bed ICU over a 12-month period as the first parameter. The incidence rates (B) will be taken from Chen et al. [61] who reported 114 episodes of bloodstream infection among 2,757 ICU admissions (giving an incidence rate of 4.1 percent). For a modeling study, this information can be used to reveal uncertainty in this parameter by fitting a beta distribution using the number of events (114) as the alpha and the number of non-events (2757-114) as the beta. This type of distribution is suitable for risks, as it produces values constrained between zero and one. The extra stay (C) per case of BSI is taken from Sheng et al. [22] who used a statistical regression model to estimate the extra stay for BSI at 15.5 days (standard deviation 24.7); this estimate is likely biased upwards because of failure to account for the timing of infection. Uncertainty in the parameter can be shown by fitting a gamma distribution to the mean and variance estimates. The procedure is to estimate...
the alpha by \((\text{mean}/\text{sd})^2\) and the beta by \((\text{sd}^2)/\text{mean}\). Treatment costs (D) are not known; but for this example we estimate they lie between $100 and $200 per case. The value of a bed day (E) is also not known; we estimate the value is between $500 and $800 per case. In the absence of better data, it is assumed both parameters are distributed uniformly.

These five parameters (A-E) can be used to generate a range of powerful outcomes, as shown by the green boxes with rounded corners in the previous figure. The modeling also shows uncertainties in the data and includes this in the output. This model (below) predicts economic outcomes of bloodstream infections for a 12-month period in one ward in Chinese Taipei; remember this model is for illustration purposes only. Table 4-1 shows the data used for estimating parameters B to E. The mean and variance are shown as well as the minimum and maximum possible values.

**Table 4-1**
*Prediction Measures and Level of Uncertainty for Each*

<table>
<thead>
<tr>
<th>Measure</th>
<th>Mean</th>
<th>Standard Deviation</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rates</td>
<td>4.13%</td>
<td>0.40%</td>
<td>2.92%</td>
<td>5.41%</td>
</tr>
<tr>
<td>Extra stay in days</td>
<td>16.5</td>
<td>26.3</td>
<td>0.0</td>
<td>200.9</td>
</tr>
<tr>
<td>Treatment cost</td>
<td>$150</td>
<td>$30</td>
<td>$100</td>
<td>$200</td>
</tr>
<tr>
<td>Bed-day cost</td>
<td>$649</td>
<td>$88</td>
<td>$500</td>
<td>$800</td>
</tr>
</tbody>
</table>

The "Rates" reflect plausible ranges of infection risks and are moderately uncertain and, Figure 4-2 shows the prior distribution of this parameter.

**Figure 4-2**
*Prior Distribution for 'Rates' Parameter*
The "extra stay in days" due to a BSI has a very high maximum value of 200 days, which shows nicely the skew in length-of-stay data (Figure 4-3). The very long stays due to infection are possible but highly unlikely to happen in the model.

**Figure 4-3**
*Prior Distribution for 'Extra Stay' Parameter*

The extra treatment costs are uniform and show close to an equal chance of being in a range of $100 to $200 (Figure 4-4).
The costs of a bed day are again uniform and show a close to equal chance of being in a range of $500 to $800 as expected (Figure 4-5).

The outputs of the modeling are shown in Table 4-2, with uncertainties included.
### Table 4-2

Economic Indicators for Hospitals and Level of Uncertainty for Each

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Mean</th>
<th>Standard Deviation</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>58</td>
<td>6</td>
<td>41</td>
<td>76</td>
</tr>
<tr>
<td>Bed-days lost</td>
<td>950</td>
<td>1512</td>
<td>0</td>
<td>10242</td>
</tr>
<tr>
<td>Total treatment costs</td>
<td>$8,692</td>
<td>$1,888</td>
<td>$4,717</td>
<td>$15,058</td>
</tr>
<tr>
<td>Cost of bed-days</td>
<td>$37,488</td>
<td>$6,078</td>
<td>$23,900</td>
<td>$58,869</td>
</tr>
<tr>
<td>Total costs</td>
<td>$46,179</td>
<td>$6,749</td>
<td>$29,277</td>
<td>$73,926</td>
</tr>
</tbody>
</table>

The number of cases from the model lies in a moderate range between 41 and 76 and reflects the uncertainty in the estimates published by Chen et al. [61] (Figure 4-6).

#### Figure 4-6

Model Output for 'Number of Cases' of BSI

The number of bed days lost to BSI follows the skew in the data, but the mean expected value is 950 days (Figure 4-7).
The value of treatment costs ranges between $4,700 and $15,000 (Figure 4-8).

The value of treatment costs ranges between $23,900 and $58,869 (Figure 4-9).
The values of the total costs range between $29,277 and $73,926, which is a reflection of the uncertainty among the input parameters. The truth is likely between these numbers and the mean value; the most likely value is $46,179.
This economic model generates some powerful data on the costs of HAIs. However, significant gaps in understanding remain in most APEC economies. We are a long way from having all the information needed to build these models for every type of site of HAIs in every APEC economy. The information in Figure 4-11 summarizes the information we have and where the major omissions are.
The green rows are the economies where we already have a good understanding of the costs of HAIs; no further work in these economies would be useful. For 10 of the remaining economies, no data exist for any of the parameters we need for economic models: Brunei, Chile, Hong Kong, Indonesia, Malaysia, Papua New Guinea, Peru, Philippines, Russian Federation, and Vietnam. Some data exist for the parameters required for the remaining APEC economies. This has been summarized in earlier sections of this report.
5. Summary

In order to assess the available body of published evidence on the economic burden of HAIs in developing economies in APEC, a thorough literature search was done and 632 published papers were reviewed. A final set of 18 publications was included. Relevant data were extracted from these studies and summarized to build and evaluate an indicative economic model. The data on incidence rates and costs of HAIs are limited and variable in both scope and quality, with only a small number of APEC counties represented. The range of infections included was variable, and the methods used to estimate extra costs were subject to biases, which are discussed. An illustrative economic model shows relevant outcomes for one of the economies. There is scope to improve the data used in the economic models and make meaningful predictions of costs in selected APEC economies. It might be that economies in which no data exists can be matched and data generalized to them. It may be that more data, currently unpublished, are available from each of the economies and can be used. Overall, the lack of accessible data in the public domain is a challenge to broader modeling. It is also clear that significant gaps exist in data that are necessary for policymakers to understand the public health and economic impact of HAIs and make informed decisions about policies and programs that could address these impacts.

A lack of data on HAIs cannot be interpreted to mean that these infections do not impose a serious economic burden on the developing economies in this analysis. In contrast, the robust body of evidence on the economic burden of HAIs in many developed economies with higher levels of infrastructure for infection prevention and control indicates that HAIs are a likely burden to all healthcare systems. A lack of robust surveillance may in fact impede the development and implementation of evidence-based policies that could enhance the efficiency and quality of healthcare systems. The evidence from this review supports the need for APEC economies to continue working toward carrying out the recommendations from the APEC High-Level Workshop on Reducing the Economic Burden of Healthcare-Associated Infections, held in July 2012 in Manila. These Manila Recommendations, as they are referred to in brief, call on APEC members to strengthen infection prevention and control programs and policies; establish surveillance and data collection; and encourage partnerships and collaboration among governments, patients, the private sector, and academia to help work towards these goals.

Making progress based on the information we have available today, while continuing to enhance the body of evidence to support continued improvement in policy and practice in infection prevention and control should be goals of policymakers in all APEC economies.
References


Appendix A. Search Strategies

HAI Costs—Search strategy and output—CINAHL

1. MH “cross infection”/(14,242)
2. hospital infection/(3,104)
3. healthcare acquired infection/(47)
4. hospital acquired infection/(409)
5. nosocomial Infection/(1,404)
6. MH health care costs/(19,523)
7. hospital costs/(1,701)
8. treatment costs/(1,682)
9. length of hospital stay/(3,527)
10. length of stay/(18,560)
11. MH ‘economics’/(5,950)
12. 1 AND 6 / (196)
13. 1 AND 7/(99)
14. 1 AND 8/(19)
15. 1 AND 6 AND 9/(19)
16. 1 AND 6 AND 10/(65)
17. 1 AND 11/(23)
18. 2 AND 6/(50)
19. 2 AND 7/(58)
20. 2 AND 8/(10)

21. 2 AND 6 AND 9/(7)
22. 2 AND 6 AND 10/(20)
23. 2 AND 11/(2)
24. 3 AND 6/(5)
25. 3 AND 7/(3)
26. 3 AND 8/(0)
27. 3 AND 6 AND 9/(3)
28. 3 AND 6 AND 10/(4)
29. 3 AND 11/(0)
30. 4 AND 6/(16)
31. 4 AND 7/(17)
32. 4 AND 8/(1)
33. 4 AND 6 AND 9/(4)
34. 4 AND 6 AND 10/(7)
35. 4 AND 11/(2)
36. 5 AND 6/(31)
37. 5 AND 7/(25)
38. 5 AND 8/(4)
39. 5 AND 6 AND 9/(6)
40. 5 AND 6 AND 10/(20)
41. 5 AND 11/(1)

42. 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41

Limiters - Date of Publication from: 01/01/2000-30/04/2013; English Language; Human / (151)
HAI Costs—Search strategy and output—CINAHL

1. MH "cross infection"/(14,242)
2. Hospital infection/(3,104)
3. Healthcare acquired infection/(47)
4. Hospital acquired infection/(409)
5. Nosocomial infection/(1,404)
6. MH health care costs/(19,523)
7. Hospital costs/(1,701)
8. Treatment costs/(1,682)
9. Length of hospital stay/(3,527)
10. length of stay/(18,560)
11. MH 'economics'/ (5,950)
12. 1 AND 6 /(196)
13. 1 AND 7/(99)
14. 1 AND 8/(19)
15. 1 AND 6 AND 9/(19)
16. 1 AND 6 AND 10/(65)
17. 1 AND 11/(23)
18. 2 AND 6/(50)
19. 2 AND 7/(58)
20. 2 AND 8/(10)

21. 2 AND 6 AND 9/(7)
22. 2 AND 6 AND 10/(20)
23. 2 AND 11/(2)
24. 3 AND 6/(5)
25. 3 AND 7/(3)
26. 3 AND 8/(0)
27. 3 AND 6 AND 9/(3)
28. 3 AND 6 AND 10/(4)
29. 3 AND 11/(0)
30. 4 AND 6/(16)
31. 4 AND 7/(17)
32. 4 AND 8/(1)
33. 4 AND 6 AND 9/(4)
34. 4 AND 6 AND 10/(7)
35. 4 AND 11/(2)
36. 5 AND 6/(31)
37. 5 AND 7/(25)
38. 5 AND 8/(4)
39. 5 AND 6 AND 9/(6)
40. 5 AND 6 AND 10/(20)
41. 5 AND 11/(1)

42. 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41

Limiters: Date of publication from 01/01/2000 to 30/04/2013; English language; Human / (151)
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>MH cross infection AND MH health care costs/(447)</td>
</tr>
<tr>
<td>2.</td>
<td>MH cross infection AND MH hospital costs/(230)</td>
</tr>
<tr>
<td>3.</td>
<td>MH cross infection AND MH health care costs AND MH length of hospital stay/(158)</td>
</tr>
<tr>
<td>4.</td>
<td>MH cross infection AND health care costs AND length of stay/(252)</td>
</tr>
<tr>
<td>5.</td>
<td>MH hospital infection AND hospital costs/(230)</td>
</tr>
<tr>
<td>6.</td>
<td>MH hospital infection AND MH health care costs AND length of hospital stay/(184)</td>
</tr>
<tr>
<td>7.</td>
<td>Health care acquired infection AND MH health care costs/(354)</td>
</tr>
<tr>
<td>8.</td>
<td>Health care acquired infection AND MH hospital costs/(117)</td>
</tr>
<tr>
<td>9.</td>
<td>Health care acquired infection AND MH health care costs AND MH length of hospital stay/(88)</td>
</tr>
<tr>
<td>10.</td>
<td>Nosocomial infection AND MH health care costs/(512)</td>
</tr>
<tr>
<td>11.</td>
<td>Nosocomial infection AND MH hospital costs/(248)</td>
</tr>
<tr>
<td>12.</td>
<td>Nosocomial infection AND MH health care costs AND MH length of hospital stay/(169)</td>
</tr>
<tr>
<td>13.</td>
<td>1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11</td>
</tr>
</tbody>
</table>

Limiters: Date of publication from 01/01/2000 to 30/04/2013; English language; Human / (475)
Appendix B. Selected Studies
<table>
<thead>
<tr>
<th>Study</th>
<th>Economy</th>
<th>Design</th>
<th>Period</th>
<th>Group</th>
<th>Infection</th>
<th>Incidence</th>
<th>Point Prevalence</th>
<th>Cost/LoS Method</th>
<th>Extra LoS (days)</th>
<th>Extra Costs/Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graves N, Nicholls TM, Morris AJ (2003) Modelling the costs of healthcare acquired infections in New Zealand. Infect Control Hosp Epidemiol, 24:214-223</td>
<td>NZ</td>
<td>Monte Carlo simulation model</td>
<td>14 May - 17 June 1999</td>
<td>All patients admitted to general medical and surgical services in Auckland District Health Board Hospitals</td>
<td>Urinary tract (UT) Surgical wound (SW); chest (CHEST); bloodstream (BS); Other (OTHER); Multiple sites (MULTI)</td>
<td>UT: 1.40% / 2.54% SW: 0.51% / 2.31% CHEST:1.04% / 1% BS: 1.77% / 0.48% OTHER: 1%/0.88% MULTI: 0.99%/0.61%</td>
<td>N/A</td>
<td>UT: 1, 5, 5.1 / 4.7, 3.6, 5.1 SW: 4, 7.5, 11 / 12, 5.7, 12.9 CHEST: 6.5, 3.7, 8.7 (for both) BS: 4, 0, 12 (both) OTHER: 2.5, 0, 12.4 (both) MULTI: 29 / 25, 18, 26.2</td>
<td>NZ$2,816 / $15,562 SW: $3,489 / $32,134 CHEST: $5,992 / $8,555 BS: $8,438 / $3,500 OTHER: $4,549 / $6,057 MULTI: $26,068 / $19,460</td>
<td></td>
</tr>
<tr>
<td>Park SY, Son JS, Oh BH, Choi JM, Lee MS. (2011). Clinical impact of methicillin-resistant Staphylococcus aureus</td>
<td>Korea</td>
<td>Propensity-matched case control</td>
<td>2003 - 2008</td>
<td>All patients with clinically significant Staphylococcus</td>
<td>MRSA, or MRSA bacteremia</td>
<td>N/A</td>
<td>Matching (1:1) Note: pair-matched</td>
<td>Mean 25.0 vs. 6.1 days</td>
<td>$9,369.6 vs. $8,555.8; P = 0.62;</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Economy</td>
<td>Design</td>
<td>Period</td>
<td>Group</td>
<td>Infection</td>
<td>Incidence</td>
<td>Point Prevalence</td>
<td>Cost/LoS Method</td>
<td>Extra LoS (days)</td>
<td>Extra Costs/Infection</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------------------</td>
<td>------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Study</td>
<td>Economy</td>
<td>Design</td>
<td>Period</td>
<td>Group</td>
<td>Infection</td>
<td>Incidence</td>
<td>Point Prevalence</td>
<td>Cost/LoS Method</td>
<td>Extra LoS (days)</td>
<td>Extra Costs/ Infection</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------</td>
<td>-------------------</td>
<td>---------------------------------</td>
<td>------------------------------------------</td>
<td>----------------------------</td>
<td>-------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 28(6):713-9</td>
<td></td>
<td></td>
<td></td>
<td>Acinetobacter baumannii bacteremia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Economy</td>
<td>Design</td>
<td>Period</td>
<td>Group</td>
<td>Infection</td>
<td>Incidence</td>
<td>Point Prevalence</td>
<td>Cost/LoS Method</td>
<td>Extra LoS (days)</td>
<td>Extra Costs/Infection</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>--------</td>
<td>--------</td>
<td>-------</td>
<td>-----------</td>
<td>-----------</td>
<td>----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Study</td>
<td>Economy</td>
<td>Design</td>
<td>Period</td>
<td>Group</td>
<td>Infection</td>
<td>Incidence</td>
<td>Point Prevalence</td>
<td>Cost/LoS Method</td>
<td>Extra LoS (days)</td>
<td>Extra Costs/Infection</td>
</tr>
<tr>
<td>---------------------------------------------------------------------</td>
<td>---------</td>
<td>--------------------------------</td>
<td>--------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>--------------------------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Higuera F, Rangel-Frausto MS, Rosenthal VD, Soto JM, Castafion J,</td>
<td>Mexico</td>
<td>Prospective, nested case-control study of patients with and without BSI</td>
<td>June 2002 – Nov. 2003</td>
<td>Patients with central venous catheter-associated BSI admitted to intensive care units (ICUs) in Mexico City.</td>
<td>Central venous catheter-associated BSI</td>
<td>10.6% over 18 months or 7.1% per year for central venous catheter-related BSI</td>
<td>N/A</td>
<td>Matching (1:1)</td>
<td>6.05 per case patient</td>
<td>N/A</td>
</tr>
</tbody>
</table>

\( LoS = \text{Length of Stay} \)